BPC-157
Animal work includes an Achilles tendon-to-bone repair experiment in rats.
TB-500
The 17–23 fragment of thymosin beta-4, not the full-length 43-amino-acid molecule.
Side-by-Side Comparison
A distinct peptide; a BPC-157 animal result does not test TB-500.
FDA identifies TB-500 as the N-terminal acetylated 17–23 fragment. Full-length thymosin beta-4 findings cannot be assigned to this fragment.
Animal work includes an Achilles tendon-to-bone repair experiment in rats.
The fragment is biologically related to thymosin beta-4, a longer molecule studied separately.
A rat model does not establish faster healing or return to function in injured people. FDA’s 2026 review also identified unresolved safety and efficacy questions for the use it assessed.
The FDA review did not identify clinical studies or reliable human exposure data for TB-500. Data on full-length thymosin beta-4 cannot be treated as direct TB-500 trial results.
FDA reviewed BPC-157 for compounding in 2026 and identified unresolved efficacy and safety questions. This is not an approved injury treatment.
FDA did not identify clinical studies or reliable human exposure data for the TB-500 fragment in its 2026 review.
Neither compound has a demonstrated human injury-recovery benefit. Rat tendon-healing findings are a reason to study BPC-157, not evidence that it speeds injury recovery in people. Ask sellers to identify the molecule and show a human study of that exact molecule before accepting a healing claim. Do not transfer a full-length thymosin beta-4 study to the shorter TB-500 fragment, or a rat tendon result to an injured person. A clinician can assess the actual injury and established care options.
Important Note
This comparison is for educational purposes only and should not replace medical advice. The best medication for you depends on your individual health profile, medical history, and personal circumstances. Always consult with a healthcare provider who can evaluate your specific situation before starting any medication.
Frequently Asked Questions
Is TB-500 the same as thymosin beta-4?
No. FDA identifies TB-500 as a short 17–23 fragment of the full-length molecule. A human study of full-length thymosin beta-4 is not a human TB-500 study.
Which one has proven tendon-healing benefits in people?
Neither. BPC-157 has a rat tendon-repair research signal; the FDA review did not identify clinical studies of the TB-500 fragment for injury recovery. Neither establishes faster recovery in an injured person.
Does combining BPC-157 and TB-500 improve recovery?
A stack has not been shown to improve a human recovery outcome. Combining two experimental substances does not create evidence for the combination or resolve identity and safety gaps.